Analysis of ocular fluid in patients with ranibizumab-recalcitrant neovascular age-related macular degeneration who have serum anti-ranibizumab antibodies-Reference-Cited by-同舟云学术

Analysis of ocular fluid in patients with ranibizumab-recalcitrant neovascular age-related macular degeneration who have serum anti-ranibizumab antibodies

Published:2023-06-15 Issue:12 Volume:261 Page:3581-3587
ISSN:0721-832X
Container-title:Graefe's Archive for Clinical and Experimental Ophthalmology
language:en
Short-container-title:Graefes Arch Clin Exp Ophthalmol

Author:

Lee Kanghoon,Lee Soyoung,Jung Soyeon,Chin Hee Seung^ORCID

Funder

Inha University Hospital research grant

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Sensory Systems,Ophthalmology

Link

https://link.springer.com/content/pdf/10.1007/s00417-023-06146-6.pdf

Reference31 articles.

1. Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431. https://doi.org/10.1056/NEJMoa054481

2. Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444. https://doi.org/10.1056/NEJMoa062655

3. Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD (2010) A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 117:2134–2140. https://doi.org/10.1016/j.ophtha.2010.02.032

4. Otsuji T, Nagai Y, Sho K et al (2013) Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD). Clin Ophthalmol 7:1487–1490. https://doi.org/10.2147/OPTH.S46317

5. Eghøj MS, Sørensen TL (2012) Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 96:21–23. https://doi.org/10.1136/bjo.2011.203893